PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321 | Completed Phase 2 Results FDA Drug

• 2 other identifiers: B78410032017-001255-31
• Study Type: interventional
• Target: 20
• Locations: 7 countries
• Sites: 8

Brief Summary

This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.

Conditions

Hemophilia A or B

Keywords

hemophilia

Outcome Measures

Primary Outcomes (6)

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related)

  An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator. Grades 3 AEs were severe and undesirable adverse events. Grades 4 AEs were life threatening or disabling adverse events.

  Day 1 up to Day 393

• Number of Participants With Abnormal Laboratory Findings Without Regard to Baseline Abnormality (Including Hematology, Serum Chemistry, and Urinalysis)

  Following parameters were analyzed for laboratory examination: hematology, clinical chemistry, and urinalysis. The hematology parameters and pre-defined criteria included: neutrophils (10\^3/millimeter\[mm\]\^3) \<0.8\*lower limit of normal (LLN), and basophils (10\^3/mm\^3) \>1.2\*upper limit of normal (ULN). The clinical chemistry parameter and pre-defined criteria included: bilirubin (milligrams \[mg\]/decilitre \[dL\]) \>1.5 ULN, aspartate aminotransferase (units \[U\]/liter \[L\]) \>3.0 ULN, glucose (mg/dL) \>1.5\*ULN. The urinalysis parameter and pre-defined criteria included: urine glucose ≥1, ketones (scalar) ≥1, urine protein ≥1, urine hemoglobin (scalar) ≥1, and hyaline casts per low power field (/LPF). Participants met criteria at any time point were included.

  Hematology and serum chemistry: Baseline, Days 1, 29, 57, 85, 169, 253, and 365 visits. Urinalysis: Baseline, Days 1, 85, 169, 253, and 365 visits.

• Number of Participants With Changes From Baseline in Vital Signs Measurements Meeting the Pre-Defined Categorical Summarization Criteria

  Following parameters were analyzed for vital sign examination: blood pressure (BP), pulse rate (PR), temperature, respiration rate. Categorical vital signs: Temperature \>38.5 degree(s) Celsius (℃), Supine PR: \<40 or \>120 beats per minute (BPM), Systolic BP: \<90 mm Hg, \>=30 mm Hg change from baseline, Diastolic BP: \<50 mm Hg, \>=20 mm Hg change from baseline.

  Baseline, Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365 and 393 visits.

• Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters Meeting the Pre-defined Categorical Summarization Criteria

  Baseline was defined as the average of triplicate ECG measurements collected prior to dosing on Day 1 in B7841003. Criteria for potentially clinically important changes in ECG were defined as: PR interval value \>=300 millisecond (msec); PR interval baseline \>200 msec and change \>=25%; PR interval baseline \<=200 msec and change \>=50%; QRS complex value \>=140 msec and change \>=50%; QTcF value \>=450 msec and change \>=30 msec. Only the number of participants meeting pre-defined criteria was reported below.

  Baseline, Days 1 and 29 visits

• Number of Participants With Abnormalities in Physical Examination Findings

  Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. For measuring weight, a scale with appropriate range and resolution was used and must have been placed on a stable, flat surface. Participants removed shoes, bulky layers of clothing, and jackets so that only light clothing remains. They also removed the contents of their pockets and remain still during measurement of weight.

  Day 1 to Day 393

• Number of Participants With Injection Site Reactions

  Injection site reactions included but were not limited to: erythema, induration, ecchymosis, pain and pruritus. Grade of severity was defined as follows: Mild: Transient or mild discomfort (\< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.

  Day 1 to Day 365, and Day 393 visit.

Secondary Outcomes (1)

• Annualized Bleeding Rate (ABR)

  Day 1 to Day 365, and Day 393 visit. Pre-Treatment summarized the data up to 6 months prior to participation in B7841003 for de novo participants and up to 6 months prior to participation in B7841002 for roll over participants.

Study Arms (6)

PF-06741086 (Cohort 1)

EXPERIMENTAL

Biological: PF-06741086

PF-06741086 (Cohort 2)

EXPERIMENTAL

Biological: PF-06741086

PF-06741086 (Cohort 3)

EXPERIMENTAL

Biological: PF-06741086

PF-06741086 (Cohort 4)

EXPERIMENTAL

Biological: PF-06741086

PF-06741086 (Cohort 5)

EXPERIMENTAL

Biological: PF-06741086

PF-06741086 (Cohort 6)

EXPERIMENTAL

Biological: PF-06741086

Interventions

PF-06741086 BIOLOGICAL

PF-06741086 subcutaneous injection

PF-06741086 (Cohort 1); PF-06741086 (Cohort 2); PF-06741086 (Cohort 3); PF-06741086 (Cohort 4); PF-06741086 (Cohort 5); PF-06741086 (Cohort 6)

Eligibility Criteria

• Age: 12 Years - 74 Years
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%)
• Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive inhibitor test result (above the upper limit of normal) at the local laboratory and must receive a bypass agent as primary treatment for bleeding episodes.
• Episodic (on-demand) treatment regimen prior to screening
• At least 6 acute bleeding episodes during the 6-month period prior to screening

You may not qualify if:

• Known coronary artery, thrombotic, or ischemic disease
• Concomitant treatment with activated prothrombin complex concentrate

Sponsors & Collaborators

• Pfizer: lead

Study Sites (8)

UC Denver Hemophilia and Thrombosis Center

Aurora, Colorado, 80045, United States

Location

Centro de Hematologia e Hemoterapia de Campinas- Hemocentro de Campinas

Campinas, São Paulo, 13083-878, Brazil

Location

Hospital Dr. Sotero del Rio

Santiago, Puente ALTO, 8207257, Chile

Location

Klinicki bolnicki centar Zagreb

Zagreb, 10000, Croatia

Location

Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne

Gdansk, 80-214, Poland

Location

Phoenix Pharma (Pty) Ltd

Port Elizabeth, Eastern Cape, 6001, South Africa

Location

Charlotte Maxeke Johannesburg Academic Hospital

Johannesburg, Gauteng, 2193, South Africa

Location

UniversitatsSpital Zurich

Zurich, 8091, Switzerland

Location

Related Publications (1)

• Mahlangu J, Luis Lamas J, Cristobal Morales J, Malan DR, Teeter J, Charnigo RJ, Hwang E, Arkin S. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 Jan;200(2):240-248. doi: 10.1111/bjh.18495. Epub 2022 Oct 11.

  PMID: 36220152 DERIVED

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Hemophilia A

Interventions

marstacimab

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2017
• First Posted: December 6, 2017
• Study Start: May 30, 2018
• Primary Completion: August 5, 2020
• Study Completion: August 5, 2020
• Last Updated: July 27, 2021
• Results First Posted: July 27, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will share

Locations

US (1); CH (1); BR (1); CL (1); CR (1); PL (1); ZA (2)